Physician profile
Bryan Michael Potthoff
NPI 1881829547
$1,971.87
in general payments reported to CMS, 2019-2025
33 companies · $984 in 2025
The $984 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.75 · 2021: $14.48 · 2022: $262 · 2023: $176 · 2024: $472 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,616 · Education: $15.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,616.03 |
| Education | $15.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $236.30 | 2024-2025 | |
| Shield Therapeutics INC | $233.39 | 2025 | |
| Abbott Laboratories | $204.14 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $188.13 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $186.65 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $118.84 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $103.89 | 2022-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Glaxosmithkline, LLC. | $63.39 | 2021-2025 | Arexvy, Shingrix, Penmenvy |
| Antares Pharma, INC. | $60.11 | 2022 | |
| Lilly USA, LLC | $57.56 | 2019-2024 | Mounjaro, Zepbound |
| Philips North America LLC | $53.39 | 2024 | (Ck4) Mcot |
| Teva Pharmaceuticals USA, INC. | $50.67 | 2025 | Austedo Xr |
| Exact Sciences Corporation | $44.45 | 2024-2025 | Cologuard Collection Kit |
| Allergan, INC. | $31.50 | 2019 | |
| Amgen INC. | $28.80 | 2024 | Prolia, Evenity |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $28.59 | 2025 | Veozah |
| Esperion Therapeutics, INC. | $26.79 | 2024 | Nexletol |
| Axonics, INC. | $22.16 | 2023 | Bulkamid |
| Myovant Sciences INC. | $20.02 | 2022 | |
| Progenics Pharmaceuticals, INC. | $19.04 | 2023 | Pylarify |
| Medtronic, INC. | $19.04 | 2024 | Intellis Adaptivestim |
| Dexcom, INC. | $17.58 | 2022 | |
| Inspire Medical Systems, INC. | $16.16 | 2025 | Inspire |
| Krystal Biotech INC | $15.96 | 2023 | Vyjuvek |
| Teleflex LLC | $15.07 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $14.99 | 2023 | Zilretta, Iovera, Exparel |
| Scpharmaceuticals INC. | $14.82 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $14.16 | 2023 | |
| Sunovion Pharmaceuticals INC. | $13.97 | 2022 | |
| Baxter Healthcare | $13.70 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Cala Health, INC. | $13.53 | 2023 | Cala Trio |
| Azurity Pharmaceuticals, INC. | $13.40 | 2024 | |
| Sanofi Pasteur INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Potthoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.